Study of VISTA Protein in Monocytes and T Cells in Multiple Sclerosis and Clinically Isolated Syndrome with 1-Year Clinical Follow-up

What this Trial Is About

Researchers are investigating the expression of VISTA, a newly identified immune regulatory protein, in monocytes and T cells of patients diagnosed with Multiple Sclerosis MS and Clinically Isolated Syndrome CIS compared to healthy individuals. The study aims to understand the role of VISTA in MS and explore its potential as a biomarker and in developing new treatments. It will also examine how VISTA expression changes over time and its clinical relevance during a 1-year follow-up. The study involves 30 people with MS and 30 healthy controls. Blood samples will be collected at the time of the first MS attack and again at 6 and 12 months to measure VISTA protein secretion and immune cell function. Different immune cell subtypes, including CD4, CD8 T cells, monocytes, and T regulatory cells, will be stimulated to analyze their pro- and anti-inflammatory responses and compare them between MS patients and healthy controls. Participants will undergo blood sampling at baseline, 6 months, and 12 months for clinical and radiological assessments. Researchers will measure VISTA protein secretion and cytokine profiles to evaluate immune cell functions and correlate these findings with clinical outcomes. The study duration spans one year, during which participants will be monitored for changes in immune responses and disease progression to better understand MS pathophysiology.

Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation